New drugs against multidrug-resistant Gram-negative bacteria: a systematic review of patents-Reference-Cited by-同舟云学术

New drugs against multidrug-resistant Gram-negative bacteria: a systematic review of patents

Published:2022-11 Issue:17 Volume:17 Page:1393-1408
ISSN:1746-0913
Container-title:Future Microbiology
language:en
Short-container-title:Future Microbiology

Author:

Jiménez María C¹,Kowalski Layza²,Souto Ricardo B³,Alves Izabel A³⁴^ORCID,Viana Max DM³^ORCID,Aragón Diana M¹^ORCID

Affiliation:

1. Departamento de Farmacia, Facultad de Ciencias, Universidad Nacional de Colombia, Bogotá D.C., Colombia

2. Department of Health Sciences, Faculty of Pharmacy, Universidade Regional Integrada do Alto Uruguai e das Missões, Santo Ângelo, RS, Brazil

3. Department of Medicines, Faculty of Pharmacy, Federal University of Bahia, Salvador, BA, Brazil.

4. Program of Post-graduation in Pharmaceutical Sciences, State University of Bahia, Salvador, BA, Brazil

Abstract

Background: Antimicrobial resistance has been a threat to human health ever since the accelerated consumption of antibiotics began. Materials & methods: The present systematic review was carried out using a free and specialized online database – Espacenet – and a survey for patents of antimicrobial agents from 2010 to 2021, selecting 33 recent patents that claimed compounds with antimicrobial activity against resistant strains of Gram-negative bacteria. Results: Some different and new approaches to the development of the patented antibacterial agents were identified, such as antimicrobial peptides, nanomaterials and natural extracts. Conclusion: Some alternatives to modern antibiotics with diminished effectiveness due to antimicrobial resistance were spotted. Nevertheless, many challenges remain to establish a robust and sustainable antibacterial R&D pipeline.

Publisher

Future Medicine Ltd

Subject

Microbiology (medical),Microbiology

Link

https://www.futuremedicine.com/doi/pdf/10.2217/fmb-2022-0104

Reference61 articles.

1. Trends of major antimicrobial resistance phenotypes in enterobacterales and gram-negative non-fermenters from ATLAS and EARS-net surveillance systems: Italian vs. European and global data, 2008-2018

2. Global priority multidrug-resistant pathogens do not resist photodynamic therapy

3. Drugs for bad bugs: confronting the challenges of antibacterial discovery

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Target identification, and optimization of dioxygenated amide derivatives as potent antibacterial agents with FabH inhibitory activity;European Journal of Medicinal Chemistry;2024-02

2. Antibacterial and Antimycotic Activity of Epilobium angustifolium L. Extracts: A Review;Pharmaceuticals;2023-10-05

3. Antibiotics in the clinical pipeline as of December 2022;The Journal of Antibiotics;2023-06-08

4. Design of Antimicrobial Peptides with Cell-Selective Activity and Membrane-Acting Mechanism against Drug-Resistant Bacteria;Antibiotics;2022-11-13